AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Amyloidosis

Recent research efforts aimed at curing Amyloidosis.

Last updated
Also available in
Français — Amyloïdose

Amyloidosis

Overview

Amyloidosis is a group of more than 15 disorders in which particular proteins misfold, form insoluble fibers called amyloid fibrils, and accumulate in organs. The two major systemic forms are light-chain (AL) amyloidosis, caused by an abnormal bone-marrow plasma-cell clone making toxic antibody light chains, and transthyretin (ATTR) amyloidosis, caused by the liver-produced transthyretin protein in inherited or wild-type disease. Deposits can damage the heart, kidneys, nerves, liver, and digestive system; the disease may therefore affect people very differently depending on the protein involved and the organs affected. Systemic amyloidosis review Amyloidosis overview (pubmed.ncbi.nlm.nih.gov)

Prognosis is especially serious when the heart is involved, and delayed diagnosis contributes to early deaths in AL amyloidosis. Current care is type-specific: AL treatment aims to eliminate the plasma-cell clone, usually with daratumumab plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd); ATTR cardiomyopathy is treated with drugs that stabilize transthyretin, such as acoramidis, or lower liver production of transthyretin, such as vutrisiran. These treatments can substantially improve outcomes, but they do not reliably eliminate all existing deposits and restore every damaged organ; there is not yet a universal cure for amyloidosis. AL diagnosis and risk assessment ANDROMEDA final analysis FDA acoramidis approval FDA 2025 drug approvals (pubmed.ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Research since 2020 has been highly active, particularly in ATTR and AL amyloidosis. The central curative questions are whether researchers can permanently stop production of the disease-causing precursor protein, physically remove established deposits from organs, and enable damaged tissue to recover. ATTR research has advanced one-time CRISPR gene editing and amyloid-clearing antibodies into late-stage development, while AL research is combining increasingly effective plasma-cell therapy with antibodies intended to clear light-chain fibrils. The field is approaching proof-of-concept for these individual components, but no approach has yet demonstrated durable, complete disease eradication across amyloidosis types. In vivo CRISPR editing for ATTR NI006 phase 1 trial CARES anselamimab results (pubmed.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

For ATTR amyloidosis, the most consequential curative-oriented strategy is to switch off the transthyretin gene in the liver. Nexiguran ziclumeran, previously called NTLA-2001, packages messenger RNA encoding the CRISPR-associated Cas9 enzyme and a guide RNA targeting the TTR gene inside lipid nanoparticles. In the first human study, one infusion produced dose-dependent reductions in circulating transthyretin: the higher initial dose reduced serum transthyretin by a mean of 87% after 28 days. Because this is permanent DNA editing in liver cells rather than repeat-dose drug suppression, it could become a functional one-time treatment if long-term efficacy and safety are confirmed. In vivo CRISPR editing for ATTR (pubmed.ncbi.nlm.nih.gov)

RNA therapeutics are a less permanent but already clinically validated way to suppress transthyretin production. Vutrisiran is a small interfering RNA, or siRNA, designed to degrade transthyretin messenger RNA in the liver. In the phase 3 HELIOS-B trial, vutrisiran improved a composite of mortality and recurrent cardiovascular events in ATTR cardiomyopathy, demonstrating that profound precursor reduction can translate into clinical benefit. Its limitation as a curative strategy is that treatment must continue and it is not designed to remove pre-existing amyloid deposits. HELIOS-B vutrisiran trial FDA 2025 drug approvals (nejm.org)

A complementary ATTR strategy is direct amyloid removal. ALXN2220, formerly NI006, is an antibody that recognizes transthyretin amyloid and is intended to recruit phagocytic immune cells, especially macrophages, to clear deposits. In a randomized phase 1 trial of 40 people with ATTR cardiomyopathy, higher doses were associated with reductions in cardiac tracer uptake and magnetic-resonance-imaging extracellular volume—measures used as indicators of cardiac amyloid burden—over 12 months. This is important because disease-modifying ATTR drugs largely prevent new deposition rather than actively clear existing cardiac amyloid. NI006 phase 1 trial (pubmed.ncbi.nlm.nih.gov)

For AL amyloidosis, a potential cure requires both suppressing the light-chain-producing plasma cells and removing accumulated fibrils. The D-VCd regimen has markedly strengthened the first component: in the 388-person phase 3 ANDROMEDA trial, hematologic complete response was 59.5% with D-VCd versus 19.2% with VCd alone, with improved overall survival after a median 61.4 months of follow-up. CAEL-101, now called anselamimab, is a fibril-binding antibody developed to address the second component. Its early phase 1a/b study found organ responses in 15 of 24 evaluable participants, but its subsequent phase 3 CARES program did not meet its primary endpoint in the overall population; a favorable signal was observed only in the smaller kappa light-chain subgroup. ANDROMEDA final analysis CAEL-101 phase 1a/b trial CARES anselamimab results (pubmed.ncbi.nlm.nih.gov)

Clinical Trials and Experimental Approaches

The phase 3 MAGNITUDE study is evaluating a single dose of nexiguran ziclumeran against placebo in people with hereditary ATTR polyneuropathy. This trial is a key test of whether the striking transthyretin reductions seen in early studies produce meaningful, sustained improvement in nerve disease without unacceptable delayed effects of permanent editing. MAGNITUDE trial (clinicaltrials.gov)

Alexion Pharmaceuticals is also conducting the phase 3 DepleTTR-CM trial of ALXN2220 versus placebo in ATTR cardiomyopathy. Its primary clinical evaluation includes all-cause mortality and cardiovascular events, moving beyond early imaging evidence of amyloid reduction. In AL amyloidosis, the two phase 3 CARES trials of anselamimab enrolled 406 people with advanced cardiac disease; the overall program missed its primary endpoint, although the kappa subgroup result remains hypothesis-generating rather than definitive. DepleTTR-CM trial CARES anselamimab results (clinicaltrials.gov)

Not all fibril-clearing antibodies have succeeded. Prothena’s birtamimab failed the primary endpoint in the phase 3 VITAL trial, despite a post-hoc signal in the sickest subgroup, and the confirmatory phase 3 AFFIRM-AL trial in Mayo stage IV AL amyloidosis was terminated after failing its primary endpoint. These results underscore the difficulty of translating apparent amyloid clearance or subgroup findings into reliable survival benefit. VITAL trial AFFIRM-AL trial record (pubmed.ncbi.nlm.nih.gov)

Methodologies and Scientific Approaches

Researchers first determine the exact precursor protein because treatment depends on amyloid type. Modern evaluation combines tissue confirmation of amyloid, protein typing by mass spectrometry, genetic testing where hereditary ATTR is suspected, and organ-specific assessments. In AL amyloidosis, serum free light chains track production by the plasma-cell clone, while cardiac biomarkers such as NT-proBNP and troponin help stage risk and measure organ response. Systemic amyloidosis review AL diagnosis and risk assessment (pubmed.ncbi.nlm.nih.gov)

Curative research combines molecular and organ-level methods. CRISPR programs use lipid nanoparticles to deliver temporary gene-editing machinery preferentially to liver cells; amyloid-depleting antibodies are evaluated with blood biomarkers, nuclear scintigraphy, cardiac magnetic resonance imaging, functional measures, and survival outcomes. Early-stage laboratories are also developing disease models, including renal AL organoids and engineered macrophages programmed to recognize AL fibrils, to test whether immune-cell therapies can improve deposit clearance before human trials. In vivo CRISPR editing for ATTR NI006 phase 1 trial Amyloidosis Foundation research program (pubmed.ncbi.nlm.nih.gov)

Leading Institutions and Funding

Major clinical and translational work is concentrated at specialist amyloidosis centers, including the National Amyloidosis Centre at University College London and Royal Free Hospital, Mayo Clinic, Boston University, Brigham and Women’s Hospital, Columbia University, Stanford University, the University of Pennsylvania, and the University of Pavia. Industry partners have been pivotal: Intellia Therapeutics and Regeneron advanced liver-directed CRISPR editing; Alexion, AstraZeneca Rare Disease, and Neurimmune advanced ALXN2220; and Alexion has sponsored the CAEL-101/anselamimab CARES program. In vivo CRISPR editing for ATTR NI006 phase 1 trial CARES anselamimab results (pubmed.ncbi.nlm.nih.gov)

Philanthropic funding supports earlier, higher-risk work that may not yet attract large commercial investment. The Amyloidosis Foundation’s 2024 junior-investigator research grants were $75,000, and its recent awardees include projects on AL CAR macrophages, protein-folding networks, renal AL organoids, deep ATTR phenotyping, and cardiac molecular imaging. NORD also offered an amyloidosis research award of up to $45,000 in 2024. Amyloidosis Foundation grant instructions Amyloidosis Foundation research program NORD amyloidosis research grant (amyloidosis.org)

Strengths, Limitations, and Challenges

The strongest recent advance is the emergence of a rational two-part framework: stop the supply of the amyloid-forming protein and remove deposits already present in organs. ATTR gene editing may eventually accomplish the first part with a single infusion, while ALXN2220 and fibril-directed AL antibodies directly test the second. In AL amyloidosis, D-VCd has proven that rapid, deep control of the plasma-cell clone improves both organ outcomes and survival. In vivo CRISPR editing for ATTR NI006 phase 1 trial ANDROMEDA final analysis (pubmed.ncbi.nlm.nih.gov)

The limitations are substantial. Permanent gene editing requires long-term monitoring for durability, off-target effects, immune reactions, and consequences of chronically very low transthyretin. Antibody studies must prove that imaging or biomarker improvements translate into longer life and restored function. AL presents additional biological complexity because kappa and lambda light chains differ, as illustrated by the overall negative CARES result and the failure of birtamimab’s confirmatory trial. Finally, amyloidosis is not a single target: a therapy that is potentially transformative for ATTR will not cure AL or inflammation-driven AA amyloidosis. CARES anselamimab results AFFIRM-AL trial record Systemic amyloidosis review (pubmed.ncbi.nlm.nih.gov)

Outlook and Future Directions

Amyloidosis research is closer to functional cures for selected forms than it was in 2020, but it is not yet at the point of claiming one. The decisive milestones will be whether MAGNITUDE shows that one-time TTR editing improves patients’ long-term neurological outcomes safely, whether DepleTTR-CM proves that antibody-mediated deposit removal improves survival and cardiovascular events, and whether future AL studies identify the right fibril-clearing therapy for biologically defined patient groups. A durable cure will likely require verified elimination or permanent suppression of the precursor protein, demonstrable clearance of organ deposits, and sustained recovery of organ function. MAGNITUDE trial DepleTTR-CM trial CARES anselamimab results (clinicaltrials.gov)

References

Don't see your disease? Request a report